Investing in Innovation Africa announces its second call for applications to support African startups in healthcare supply chains
Applications are open for early and growth-stage health tech innovators
Source: africa.com
📰 Merck Sharp News
Page 39 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
Investing in Innovation Africa announces its second call for applications to support African startups in healthcare supply chains
Applications are open for early and growth-stage health tech innovators
Source: africa.com
Article: Biden's Blarney: What Joe Biden Did Not Say to the Irish Parliament
Article: Bidens Blarney: What Joe Biden Did Not Say to the Irish Parliament - President Biden played nice with Ireland when he should have read them the riot act. Ireland has been stealing jobs from the United States for 30 years with its low corporate income tax.
Source: opednews.com
The Great Nitrosamine Audit: how many more drugs will disappear from our shelves?
The Pharmaceutical Journal from the Royal Pharmaceutical Society
United Kingdom Andrew Teasdale Michael White Aventis Pharma Ltd European Federation Of Pharmaceutical Industries European Medicines Agency
Source: pharmaceutical-journal.com
DelveInsight Business Research, LLP: Next-Generation Immunotherapies Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Regeneron, Boehringer Ingelheim, Sanofi, AstraZeneca, Roche, Merck, Incyte, GSK, Novartis
Next-generation immunotherapies market is expected to grow significantly during the forecast period (2023-2032) owing to the increasing number of cancer cases in the 7MM, accompanied by the
Bristol Myers Squibb Hubao Biopharm Shruti Thakur Boehringer Ingelheim Roche Ltd Immutep Incyte Corporation
Source: finanznachrichten.de
Nykode Therapeutics : Final Results from the Phase 2 VB-C-02 trial – presentation
VB10.16 Final Phase 2 data readout - 12 month treatment follow up April 19 2023 ... | April 19, 2023
Source: marketscreener.com
Belzutifan Plus Cabozantinib Deemed Promising for Advanced RCC
Combination treatment with belzutifan and cabozantinib has demonstrated antitumor activity in previously treated, advanced clear cell renal cell carcinoma.
Source: renalandurologynews.com
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial | Colorectal Cancer | JAMA
This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients w
Source: jamanetwork.com
Pemigatinib Demonstrates Activity in Previously Treated Solid Tumors Harboring Activating FGFR Alterations
Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.
Source: onclive.com
Adjuvant regimen has 'potential' to change practice in high-risk liver cancer
Adjuvant treatment with atezolizumab and bevacizumab extended RFS compared with active surveillance among patients with hepatocellular carcinoma, according to study findings presented at AACR Annual Meeting.The combination exhibited a generally manageable safety profile, results of the randomized phase 3 IMbrave050 trial showed.
United States Mindy Valcarcel Bymark Leiser Roche Ltd National Cancer Centre Singapore American Association For Cancer Research Annual Meeting
Source: healio.com